hVIVO has unveiled its state-of-the-art outpatient facility in Whitechapel, London, marking a significant expansion in its clinical site services. This modern unit is designed to enhance the efficiency and effectiveness of vaccine and therapeutic studies, reflecting hVIVO’s commitment to advancing medical research.
The Whitechapel clinic offers comprehensive services tailored to the needs of vaccine Phase II-III trials and respiratory clinical trials. Equipped with cutting-edge technology and staffed by a team of experts, the facility ensures high-quality data collection and participant safety. Its strategic location in Whitechapel provides convenient access for participants, facilitating streamlined recruitment and retention.
Investors will appreciate hVIVO’s integrated approach to drug development. The company’s services span from preclinical stages through Phase II trials, with patient recruitment supported by FluCamp. This holistic model not only accelerates the development timeline but also optimises resource utilisation, offering a compelling proposition for stakeholders.
hVIVO’s leadership in human challenge trials and laboratory services positions it at the forefront of clinical research. The Whitechapel facility exemplifies the company’s dedication to innovation and excellence, reinforcing its role as a trusted partner in the pharmaceutical and biotechnology sectors.
hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
